Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) quarterly balance sheet — complete assets, liabilities & equity history
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) balance sheet — 2-year assets, liabilities & shareholders' equity history
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|
| Total Current Assets | 14.89K | 12.19K | 28.2K | 49.73K | 71.02K | 5 | 2.1K | 78 |
| Cash & Short-Term Investments | - | - | - | - | - | - | - | - |
| Cash Only | - | - | - | - | - | - | - | - |
| Short-Term Investments | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 6.05K | 27.48K | 48.9K | 0 | -4.99K | 0 | 0 |
| Total Non-Current Assets | 242.02M | 239.91M | 237.6M | 235.16M | 232.74M | 546 | 424.04K | 113 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 242.02M | 0 | 238.21M | 235.85M | 233.59M | 0 | 0 | 0 |
| Other Non-Current Assets | - | - | - | - | - | - | - | - |
| Total Assets | 242.04M | 239.92M | 237.63M | 235.21M | 232.81M | 551 | 426.14K | 191 |
| Asset Turnover | - | - | - | - | - | - | - | - |
| Asset Growth % | 3.96% | 43556253.21% | 55664.06% | 99999900% | - | - | - | - |
| Total Current Liabilities | 492.17K | 376.17K | 456.61K | 301.44K | 347.37K | 796 | 591K | 211 |
| Accounts Payable | 238.18K | 222.18K | 302.62K | 147.45K | 132.48K | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - |
| Short-Term Debt | 100K | 0 | 0 | 0 | 60.9K | 662 | 552.01K | 210 |
| Deferred Revenue (Current) | - | - | - | - | - | - | - | - |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 56 | 38.98K | 1 |
| Current Ratio | 0.03x | 0.03x | 0.06x | 0.16x | 0.20x | 0.01x | 0.00x | 0.37x |
| Quick Ratio | 0.03x | 0.03x | 0.06x | 0.16x | 0.20x | 0.01x | 0.00x | 0.37x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.9M | 6.9M | 6.9M | 6.9M | 6.9M | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | - | - | - | - | - | - | - | - |
| Deferred Tax Liabilities | - | - | - | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - | - | - | - |
| Total Liabilities | 7.39M | 7.28M | 7.36M | 7.2M | 7.25M | 796 | 591K | 211 |
| Total Debt | 100K | 0 | 0 | 0 | 60.9K | 662 | 552.01K | 210 |
| Net Debt | 85.11K | -6.14K | -717 | -822 | 59.98K | 661 | 549.92K | 192 |
| Debt / Equity | 0.00x | - | - | - | 0.00x | - | - | - |
| Debt / EBITDA | - | - | - | - | - | 756.94x | - | - |
| Net Debt / EBITDA | - | - | - | - | - | 755.40x | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | 234.64M | 232.64M | 230.28M | 228M | 225.56M | -244 | -164.86K | -20 |
| Equity Growth % | 4.03% | 95345458.61% | 139780.46% | 99999900% | - | - | - | - |
| Book Value per Share | 10.20 | 11.07 | 10.01 | 6.80 | 8.84 | -0.00 | -0.02 | -0.00 |
| Total Shareholders' Equity | 234.64M | 232.64M | 230.28M | 228M | 225.56M | -244 | -164.86K | -20 |
| Common Stock | 242.02M | 239.91M | 237.61M | 235.16M | 232.74M | 986 | 986 | 1 |
| Retained Earnings | -7.38M | -7.27M | -6.72M | -6.46M | -6.33M | -279 | -199.86K | -55 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |